AS1842856 Reduces β-Amyloid Burden via Inhibiting PLA2G4A-Mediated Lysosomal Dysfunction in APP/PS1 Mice

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Lysosomal dysfunction and PLA2G4A activation are implicated in neurodegeneration.
• GSK3α/β signaling pathways may regulate lysosomal function and neurodegenerative processes.
• AS1842856 (AS) is a known suppressor of GSK3α/β.

Purpose of the Study:

• To investigate if AS mitigates Alzheimer's disease (AD) progression.
• To determine if AS targets PLA2G4A to restore lysosomal homeostasis.
• To explore the therapeutic potential of AS in AD models.

Main Methods:

• Therapeutic potential of AS assessed in APP/PS1 mice and N2a-sw cells.
• Evaluated cognitive function, β-amyloid (Aβ) load, and lysosomal integrity.
• Investigated the mechanism of action involving GSK3α/β, PLA2G4A, and NF-κB signaling.

Main Results:

• AS treatment reduced GSK3α/β and PLA2G4A expression.
• Lysosomal membrane integrity was restored, enhancing Aβ degradation.
• AS administration improved cognitive function and reduced Aβ burden in mice.
• AS inhibited NF-κB-mediated PLA2G4A expression; GSK3β knockdown mimicked AS effects.

Conclusions:

• The GSK3β/NF-κB/PLA2G4A signaling axis is a novel therapeutic target for AD.
• AS inhibits this axis, mitigating Aβ pathology via enhanced lysosomal degradation.
• AS shows promise in treating Alzheimer's disease by restoring lysosomal homeostasis.